偏头痛患者在β-肾上腺素能受体阻滞剂治疗前及治疗期间的血小板P1，P4-二（腺苷-5′）四磷酸（AP4A）

Platelet P1, P4-Di (adenosine-51) tetraphosphate (AP4A) in migraine patients before and during beta-adrenoceptor blockade.

作者信息

Winther K, Hedman C, Flodgaard H

机构信息

Department of Clinical Chemistry, Frederiksberg and Hvidovre Hospital, Copenhagen, Denmark.

出版信息

Eur J Clin Invest. 1990 Jun;20(3):336-8. doi: 10.1111/j.1365-2362.1990.tb01866.x.

DOI:10.1111/j.1365-2362.1990.tb01866.x

PMID:2164477

Abstract

P1,P4-Di(adenosine-51) tetraphosphate (AP4A) is a metabolically inactive nucleotide which can be released from platelet dense granules. This study was designed firstly, to investigate whether platelet content of AP4A was decreased in patients with classical migraine and secondly, whether the content of AP4A was changed by beta-adrenoceptor blockade. No significant difference in platelet dense granule content of AP4A, was observed between 10 migraine patients and 10 normal controls. Both metoprolol, a beta 1-selective blocker and propranolol, a non-selective beta-blocker significantly decreased the migraine attack rate. However, while propranolol significantly reduced the platelet content of AP4A, metoprolol did not. Therefore, the present data suggest that platelet dense granule release, as estimated by the content of AP4A is not of major importance in migraine.

摘要

P1，P4 - 二（腺苷 - 5′）四磷酸（AP4A）是一种代谢无活性的核苷酸，可从血小板致密颗粒中释放出来。本研究旨在：其一，调查典型偏头痛患者血小板中AP4A含量是否降低；其二，β - 肾上腺素能受体阻断是否会改变AP4A的含量。在10名偏头痛患者和10名正常对照者之间，未观察到血小板致密颗粒中AP4A含量有显著差异。β1选择性阻滞剂美托洛尔和非选择性β阻滞剂普萘洛尔均显著降低了偏头痛发作率。然而，普萘洛尔显著降低了血小板中AP4A的含量，而美托洛尔则没有。因此，目前的数据表明，以AP4A含量估计的血小板致密颗粒释放，在偏头痛中并非至关重要。